Literature DB >> 25693858

Continuous infusion of angiotensin II modulates hypertrophic differentiation and apoptosis of chondrocytes in cartilage formation in a fracture model mouse.

Hirohisa Kawahata1, Daisuke Sotobayashi2, Motokuni Aoki2, Hideo Shimizu3, Hironori Nakagami3, Toshio Ogihara2, Ryuichi Morishita4.   

Abstract

Although components of the renin-angiotensin system (RAS) are reported to be expressed in cultured chondrocytes and cartilage, little is known about the precise function of Angiotensin II (Ang II) in chondrocytes. In this study, we employed a rib fracture model mouse to investigate the effect of Ang II on chondrocytes. Ang II type 1 receptor (AT1R) was expressed in chondrocytes in the growth plate of mouse tibia. Continuous infusion of Ang II to rib-fractured mice resulted in a significant increase in the volume of cartilage, suggesting Ang II-induced hypertrophic differentiation of chondrocytes. It was also confirmed by a significant increase in the mRNA expression of Sox9 and runt-related transcription factor 2 (Runx2), which are genes related to chondrocyte differentiation, and type X collagen, matrix metalloproteinase (MMP)-13 and Indian hedgehog (Ihh), which are hypertrophic chondrocyte-specific molecular markers. Chondrocyte hypertrophy with upregulation of these genes was attenuated by administration of olmesartan, an AT1R blocker, but not by hydralazine. Moreover, Ang II infusion significantly suppressed apoptosis of chondrocytes, accompanied by significant induction of mRNA expression of bcl-2 and bcl-xL. Olmesartan, but not hydralazine, significantly attenuated the reduction of apoptotic cells and the increase in anti-apoptotic genes induced by Ang II infusion. Overall, the present study demonstrated that Ang II promoted hypertrophic differentiation of chondrocytes and reduced apoptosis of hypertrophic chondrocytes independently of high blood pressure. The present data indicate the role of Ang II in cartilage, and might provide a new concept for treatment of cartilage diseases.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25693858     DOI: 10.1038/hr.2015.18

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  62 in total

1.  Baicalein attenuates angiotensin II-induced cardiac remodeling via inhibition of AKT/mTOR, ERK1/2, NF-κB, and calcineurin signaling pathways in mice.

Authors:  Ai-Wu Wang; Lina Song; Jie Miao; Hong-Xia Wang; Cui Tian; Xue Jiang; Qiu-Yue Han; Liqing Yu; Ying Liu; Jie Du; Yun-Long Xia; Hui-Hua Li
Journal:  Am J Hypertens       Date:  2014-10-31       Impact factor: 2.689

2.  Effect of angiotensin II receptor blocker, olmesartan, on turnover of bone metabolism in bedridden elderly hypertensive women with disuse syndrome.

Authors:  Motokuni Aoki; Hirohisa Kawahata; Daisuke Sotobayashi; Hisahiro Yu; Atsushi Moriguchi; Hironori Nakagami; Toshio Ogihara; Ryuichi Morishita
Journal:  Geriatr Gerontol Int       Date:  2014-11-03       Impact factor: 2.730

3.  Locally produced estrogen promotes fetal rat metatarsal bone growth; an effect mediated through increased chondrocyte proliferation and decreased apoptosis.

Authors:  A S Chagin; D Chrysis; M Takigawa; E M Ritzen; L Sävendahl
Journal:  J Endocrinol       Date:  2006-02       Impact factor: 4.286

Review 4.  Physiology of local renin-angiotensin systems.

Authors:  Martin Paul; Ali Poyan Mehr; Reinhold Kreutz
Journal:  Physiol Rev       Date:  2006-07       Impact factor: 37.312

5.  Angiotensin II is generated from angiotensin I by bone cells and stimulates osteoclastic bone resorption in vitro.

Authors:  R Hatton; M Stimpel; T J Chambers
Journal:  J Endocrinol       Date:  1997-01       Impact factor: 4.286

6.  Estrogen receptor specificity in the regulation of skeletal growth and maturation in male mice.

Authors:  O Vidal; M K Lindberg; K Hollberg; D J Baylink; G Andersson; D B Lubahn; S Mohan; J A Gustafsson; C Ohlsson
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-09       Impact factor: 11.205

7.  Clock genes influence gene expression in growth plate and endochondral ossification in mice.

Authors:  Takeshi Takarada; Ayumi Kodama; Shogo Hotta; Michihiro Mieda; Shigeki Shimba; Eiichi Hinoi; Yukio Yoneda
Journal:  J Biol Chem       Date:  2012-08-30       Impact factor: 5.157

8.  Angiotensin receptor blockers suppress antigen-specific T cell responses and ameliorate collagen-induced arthritis in mice.

Authors:  Kayo Sagawa; Katsuya Nagatani; Yoshinori Komagata; Kazuhiko Yamamoto
Journal:  Arthritis Rheum       Date:  2005-06

9.  Blocking angiotensin-converting enzyme induces potent regulatory T cells and modulates TH1- and TH17-mediated autoimmunity.

Authors:  Michael Platten; Sawsan Youssef; Eun Mi Hur; Peggy P Ho; May H Han; Tobias V Lanz; Lori K Phillips; Matthew J Goldstein; Roopa Bhat; Cedric S Raine; Raymond A Sobel; Lawrence Steinman
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-19       Impact factor: 11.205

Review 10.  A century old renin-angiotensin system still grows with endless possibilities: AT1 receptor signaling cascades in cardiovascular physiopathology.

Authors:  Pitchai Balakumar; Gowraganahalli Jagadeesh
Journal:  Cell Signal       Date:  2014-07-05       Impact factor: 4.315

View more
  7 in total

1.  Antihypertensive medications and the risk of kidney stones in older adults: a retrospective cohort study.

Authors:  R Todd Alexander; Eric McArthur; Racquel Jandoc; Blayne Welk; Jade S Hayward; Arsh K Jain; Branko Braam; Veit Flockerzi; Amit X Garg; Robert Ross Quinn
Journal:  Hypertens Res       Date:  2017-03-23       Impact factor: 3.872

2.  Angiotensin type 2 receptor antagonism as a new target to manage gout.

Authors:  Luiz Ricardo Goulart; Thiago Neves Vieira; André L Lopes Saraiva; Rafaela Mano Guimarães; João Paulo Mesquita Luiz; Larissa Garcia Pinto; Veridiana de Melo Rodrigues Ávila; Jair Pereira Cunha-Junior; Peter Anthony McNaughton; Thiago Mattar Cunha; Juliano Ferreira; Cassia Regina Silva
Journal:  Inflammopharmacology       Date:  2022-09-29       Impact factor: 5.093

Review 3.  Hypertension meets osteoarthritis - revisiting the vascular aetiology hypothesis.

Authors:  Karen Ching; Xavier Houard; Francis Berenbaum; Chunyi Wen
Journal:  Nat Rev Rheumatol       Date:  2021-07-27       Impact factor: 20.543

4.  Captopril, an angiotensin-converting enzyme inhibitor, possesses chondroprotective efficacy in a rat model of osteoarthritis through suppression local renin-angiotensin system.

Authors:  Yang Tang; Xiaopeng Hu; Xiongwei Lu
Journal:  Int J Clin Exp Med       Date:  2015-08-15

5.  Fatty acids derived from apoptotic chondrocytes fuel macrophages FAO through MSR1 for facilitating BMSCs osteogenic differentiation.

Authors:  Zi-Yang Zheng; Tao Jiang; Zhen-Fei Huang; Bo Chu; Jun Gu; Xuan Zhao; Hao Liu; Jin Fan; Li-Peng Yu; Shu-Heng Jiang; Qing Li; Li-Peng Hu; Fan-Qi Kong; Lai Zhang; Qi Chen; Jian Chen; Han-Wen Zhang; Guo-Yong Yin; Shu-Jie Zhao
Journal:  Redox Biol       Date:  2022-04-30       Impact factor: 10.787

6.  [Expressions of Renin, angiotensin converting enzyme, angiotensin receptor 1, and angiotensin receptor 2 in synovial tissue of osteoarthritis at different stages].

Authors:  Yuangang Wu; Yi Zeng; Mingyang Li; Yuan Liu; Jing Yang; Bin Shen
Journal:  Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi       Date:  2020-03-15

7.  Aliskiren has chondroprotective efficacy in a rat model of osteoarthritis through suppression of the local renin-angiotensin system.

Authors:  Kaizhong Yan; Yixin Shen
Journal:  Mol Med Rep       Date:  2017-07-28       Impact factor: 2.952

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.